-
The pharmaceutical rivers and lakes are surging, and a group of local pharmaceutical company executives have returned to multinational pharmaceutical companies!
Time of Update: 2022-04-15
According to the data, Qian Wei has more than 25 years of rich experience in the pharmaceutical industry, and has worked in large multinational pharmaceutical companies such as Eli Lilly, AstraZeneca, and Roche .
-
The inflection point of the traditional Chinese medicine industry has come, and the Nuggets have 3 sub-tracks
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In recent years, with the establishment and improvement of industry standards, mechanisms and service systems, the traditional Chinese medicine industry has gradually presented a good situation of equal emphasis on traditional Chinese and Western medicine, support and regulation, inheritance and innovation.
-
Technological innovation is making pharmaceutical equipment companies glow with "new vitality"
Time of Update: 2022-04-15
Technological innovation is bringing "new vitality" to pharmaceutical equipment companies (Source: Pharmaceutical Network) For example, on January 10, Tofflon's 2021 performance pre-increase announcement showed that the expected net profit is 765 million yuan to 9.
-
Strong pharmaceutical demand drives the development of pharmaceutical machines, and many companies such as Canaan Technology have achieved gratifying performance
Time of Update: 2022-04-15
Regarding the changes in performance, Canaan Technology said that during the reporting period, the company continued to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses in the entire industry chain to ensure the company's oral solid preparation equipment, biological preparation fluid equipment and various businesses.
-
The pharmaceutical equipment industry is developing rapidly, and the market prospect of tangential flow filtration is optimistic
Time of Update: 2022-04-15
The pharmaceutical equipment industry is developing rapidly, and the market prospect of tangential flow filtration is promising.
Overall, there are relatively few domestic manufacturers with independent research and development capabilities in the domestic tangential flow filtration market, and their brand strength is not as strong as that of foreign-funded enterprises.
-
Strategy for the second quarter of 2022 in the pharmaceutical field: overall or relatively stable, investment still needs to be carefully selected
Time of Update: 2022-04-15
The agency predicts that according to the performance of Zhaoyan New Drug, the company's net profit in 2022-2023 is expected to be 730 million, 920 million, and 2022-2023 EPS will be 1.
-
10 boards in 12 days!
Time of Update: 2022-04-15
According to the 2021 third quarter report released by Panlong Pharmaceutical, the company achieved a total operating income of 623 million yuan in the first three quarters of 2021, a year-on-year increase of 37.
-
Under the escort of the policy, the Chinese medicine industry is expected to usher in a new life!
Time of Update: 2022-04-15
Among them, in terms of the traditional Chinese medicine formula granule business, the company continued to strengthen the national production capacity layout, continued to improve the market coverage and the penetration rate of the stock market, and achieved a significant increase in revenue and profit compared with the same period of the previous year .
-
Opportunities and challenges coexist in the traditional Chinese medicine formula granule industry, how should enterprises respond?
Time of Update: 2022-04-15
In the context of the ever-changing environment in the pharmaceutical industry, the company continues to carry out innovation, transformation and upgrading, strengthen brand and channel construction, increase innovation investment, improve operational quality and efficiency, and stabilize its position in the industry.
-
Is there an opportunity for a strong layout in medicine?
Time of Update: 2022-04-15
As a representative of the CRO (pharmaceutical R&D contract outsourcing service organization) industry, the operating performance of Zhaoyan New Drug, a listed company, continued to rise sharply .
-
Industry: The domestic pharmaceutical equipment industry has ushered in the third opportunity for rapid development
Time of Update: 2022-04-15
Pharmaceutical equipment (photo source: Pharmaceutical Network) In terms of the current domestic biopharmaceutical equipment market scale, data shows that in 2020, China's biopharmaceutical equipment and consumables represented by reactor systems, disposable reaction bags, chromatography equipment, etc.
-
The Chinese medicine market has opened up, and institutions have been investigating!
Time of Update: 2022-04-15
For example, Zhenbao Island stated in its investor relations activity record sheet released on March 29 that the company accepted four institutional surveys on March 25, 2022, with the types of institutions being insurance companies, fund companies, and securities companies .
-
After the medical insurance of traditional Chinese medicine formula granules can be reimbursed, the market will accelerate the expansion
Time of Update: 2022-04-15
According to the "Notice", qualified Chinese medicine formula granules, after being reviewed by experts, will be included in the payment scope of the basic medical insurance fund of Fujian Province according to 70% of the sales price, and the limited payment scope of the corresponding Chinese medicine decoction pieces will be implemented with reference to the regulations .
-
In 2022, these traditional Chinese medicine subdivisions may break out!
Time of Update: 2022-04-15
The industry believes that the future expansion of the traditional Chinese medicine formula market is expected to accelerate, and the filing system and the new national standard will build high industry barriers .
-
Strengthening the supervision of medical devices in many places, equipment companies are facing big challenges
Time of Update: 2022-04-15
For example, in order to strengthen the supervision of online sales enterprises of medical devices and improve the level of quality and safety management, the Market Supervision Bureau of Wuqing District, Tianjin recently launched the 2022 governance action of "online and offline regulations" for medical devices, both online and offline.
-
How to open the ceiling of the pharmaceutical equipment industry?
Time of Update: 2022-04-15
In recent years, innovative drugs including antibody drugs, cell therapy, and gene drugs have flourished, bringing new development opportunities to the upstream equipment and consumables industries .
-
Pension concept stocks continue to be popular, and many stocks such as Yuexin Health have daily limit
Time of Update: 2022-04-15
Several pharmaceutical stocks involving the concept of elderly care have risen sharply today, including Yuexin Health, Dongcheng Pharmaceutical, Dean Diagnostics, Xiangyu Medical, Taiji Group, etc.
The two parties plan to jointly initiate the establishment of Nuokai Dongcheng Nuclear Pharmaceutical Industry Investment fund (limited partnership) with a fund size of 500 million yuan .
-
1 new pharmaceutical stock is subscribed today, focusing on the field of domestic small molecule innovative drugs
Time of Update: 2022-04-15
This product is the second-generation ALK kinase inhibitor independently developed by the company, which is used for the treatment of advanced ALK-positive non-small cell lung cancer.
-
The Centralized Procurement Alliance of Chinese Patent Medicines in 6 Provinces is approaching, and a large number of medicines will be reduced in price
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In recent years, many places have carried out centralized procurement pilots for some varieties of Chinese patent medicines with high demand and high price .
-
The new pharmaceutical shares listed on the Science and Technology Innovation Board have been losing money for four consecutive years!
Time of Update: 2022-04-15
For example, in the domestic NMIBC field, in addition to Asieris' APL-1202, there are 6 innovative drugs of other companies in clinical stage; In the field of HSIL treatment, there are also 3 domestic therapeutic drugs targeting HSIL or CIN2/3 that have entered clinical trials .
